Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arrowhead Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute

61 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Industria
Igiene alimentare
Salute
Scienza
Farmaceutica
Biotecnologia
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/12/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Eventi
Fiere
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/11/2025
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Mercato azionario
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Sanità
Scienza
Farmaceutica
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Cardiologia
Igiene alimentare
Salute
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Web e Social Network
Eventi
Fiere
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Sanità
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/10/2025
Assistenza all'Infanzia
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Biotecnologia
Salute
Medicina - Varie
Cardiologia
Farmaceutica
Mercato azionario
Finanza
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
21/10/2025
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Biologia
Salute
Farmaceutica
Mercato del lavoro
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0